Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355303 | 1.00 | OPRK1 (0.60) | OPRK1ALDH1A1MAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL4780269 | 0.98 | OPRK1 (0.58) | OPRK1ALDH1A1MAPTNFKB1THPO | |
| SCHEMBL459393 | 0.93 | DRD2 (0.60) | OPRK1ALDH1A1MAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL355061 | 0.92 | DRD2 (0.58) | OPRK1ALDH1A1MAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL12505562 | 0.92 | DRD2 (0.58) | OPRK1ALDH1A1MAPTNFKB1THPO | |
| Hydrochloric Acid SCHEMBL6642375 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MAPTKDM4E | |
| SCHEMBL353908 | 0.81 | OPRK1 (0.54) | OPRK1DRD2DRD3 | |
| SCHEMBL8537094 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTDRD3KDM4E | |
| SCHEMBL7275357 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTDRD3KDM4E | |
| Hydrochloric Acid SCHEMBL353391 | 0.80 | OPRK1 (0.53) | OPRK1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188273-B1 | SUBSTITUTED TETRA HYDRO NAPHTHALINES, METHOD FOR THEIR MANUFACTURE AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2014-10-22 | — | — | EP | disclosed |
| US-8841290-B2 | Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs | SANOFI (FR) | 2014-09-23 | — | — | US | disclosed |
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI (FR) | 2014-03-27 | — | — | US | disclosed |
| US-8609731-B2 | Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2012-01-19 | — | — | US | disclosed |
| EP-2396300-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI (FR) | 2011-12-21 | — | — | EP | disclosed |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| WO-2010092153-A1 | NEW SUBSTITUTED TETRAHYDRONAPTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | SANOFI-AVENTIS (FR) | 2010-08-19 | — | — | WO | disclosed |
| EP-2188273-A2 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009021740-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | SANOFIS-AVENTIS (FR) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025674-A1 | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs | sanofi-aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088077-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | OPRK1 912/4885ALDH1A1 863/4885MAPT 2031/4885 |
| US-20100249097-A1 | NOVEL SUBSTITUTED TETRAHYDRONAPHTHALENES, PROCESS FOR THE PREPARATION THEREOF AND THE USE THEREOF AS MEDICAMENTS | DHPS, CYP11B2, CYP11B1 | OPRK1 912/4885ALDH1A1 863/4885MAPT 2031/4885 |
| US-20120015936-A1 | SUBSTITUTED TETRAHYDRONAPHTHALENES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF AS DRUGS | PAH, MCHR1, DHPS | OPRK1 147/4885ALDH1A1 1247/4885MAPT 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.